id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-N-3771-0007,FDA,FDA-2018-N-3771,Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments; Availability,Notice,Notice of Availability,2022-04-21T04:00:00Z,2022,4,2022-04-21T04:00:00Z,,2022-04-21T13:18:27Z,2022-08499,0,0,0900006485029c13